## Drug Summary
Hydroxyamitriptyline, also known as 10-hydroxyamitriptyline, is an active metabolite of the tricyclic antidepressant (TCA) amitriptyline. It is primarily formed in the liver through the metabolic action of cytochrome P450 isoenzymes, mainly CYP2D6. Amitriptyline and its metabolites, including hydroxyamitriptyline, exhibit antidepressant effects by inhibiting the reuptake of neurotransmitters in the central nervous system, specifically norepinephrine and serotonin, leading to increased synaptic concentrations of these neurotransmitters. The pharmacodynamics of hydroxyamitriptyline are similar to that of the parent compound, contributing to its overall antidepressant efficacy though it has a somewhat lower potency compared to amitriptyline.

## Drug Targets, Enzymes, Transporters, and Carriers
Due to the lack of specific information on hydroxyamitriptyline from the provided DrugBank data and limited specific details in typical sources, we can infer that its targets, enzymes, transporters, and carriers are likely to overlap significantly with those of its parent drug, amitriptyline. Amitriptyline primarily targets serotonin transporter (SERT) and norepinephrine transporter (NET) for its antidepressant action. It is metabolized in the liver by CYP2D6 and other CYP450 enzymes. Transporters potentially involved in its pharmacokinetics include the organic cation transporters which play a role in the renal excretion of tricyclic antidepressants.

## Pharmacogenetics
Pharmacogenetically, the metabolism of hydroxyamitriptyline is significantly influenced by the genetic variability of CYP2D6, the enzyme primarily responsible for the metabolism of its parent compound, amitriptyline, to hydroxyamitriptyline. Variations in the CYP2D6 gene can drastically affect the drugâ€™s plasma levels and thereby its therapeutic efficacy and toxicity. Poor metabolizers (PMs) of CYP2D6 might experience higher concentrations and potential toxicity, whereas ultra-rapid metabolizers (UMs) might have reduced drug efficacy due to rapid clearance. Adjustments in dosing may be necessary based on CYP2D6 genotype to optimize therapeutic outcomes and minimize adverse effects.